IP Library Granted Patent US 10,918,586
Granted Patent B2
US 10,918,586 · App. 16/208,646 · Granted Feb 16, 2021

Topical compositions and methods of use thereof

Inventor: Gerald Horn (Deerfield, IL)
Assignee: PS Therapy Ltd.
A61K8/66A61K8/20A61K8/345A61K8/368A61K8/38A61K8/39A61K8/4973A61K8/64A61K8/731A61K8/738A61K8/84A61K8/86A61K8/922A61K31/00A61K31/327A61K31/60A61K38/4893A61P17/10A61Q19/00A61Q19/08C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,918,586
App. No.
16/208,646
Granted
Feb 16, 2021
Kind
B2
Abstract

The present invention is directed to topical compositions containing botulinum toxin, benzoyl peroxide, salicylic acid or a mixture of benzoyl peroxide and salicylic acid. The present invention is further directed to methods of treating acne or reducing rhytides with these topical compositions.

Claims (32)

1. A topical composition comprising botulinum toxin, polysorbate 80, poloxamer 407, poloxamer 188, polyoxyl castor oil, hydroxypropyl-gamma-cyclodextrin, hydroxypropylmethyl cellulose, mannitol, magnesium chloride, and sodium chloride.

2. The composition of claim 1 , comprising:

from about 50 to about 200 units of botulinum toxin;

from about 0.5% to about 3.5% w/v polysorbate 80;

from about 0.2% to about 0.5% w/v poloxamer 407;

from about 0.1% to about 1.5% w/v poloxamer 188;

from about 0.015% to about 0.5% w/v polyoxyl castor oil;

from about 0.5% to about 5.0% w/v hydroxypropyl-gamma-cyclodextrin;

from about 0.5% to about 1.25% w/v hydroxypropylmethyl cellulose;

from about 0.5% to about 1.0% w/v polyethylene glycol 400;

from about 1.0% to about 4.0% w/v mannitol;

from about 0.075% to about 0.125% w/v magnesium chloride; and

from about 0.1% to about 0.5% w/v sodium chloride,

wherein w/v denotes weight by total volume of the composition.

3. The composition of claim 2 , further comprising from about 0.1 to about 0.5 millimolar menthol.

4. The composition of claim 3 , further comprising from about 0.005% to about 0.02% w/v benzalkonium chloride and from about 0.05% to about 0.15% w/v disodium ethylenediaminetetraacetic acid.

5. A topical composition comprising:

about 100 units of botulinum toxin;

about 3.0% w/v polysorbate 80;

about 0.2% w/v poloxamer 407;

about 1.5% w/v poloxamer 188;

about 0.5% w/v polyoxyl castor oil;

about 1.5% w/v hydroxypropyl-gamma-cyclodextrin;

about 0.75% w/v hydroxypropylmethyl cellulose;

about 0.5% w/v polyethylene glycol 400;

about 1.0% w/v mannitol;

about 0.1% w/v magnesium chloride; and

about 0.4% w/v sodium chloride,

wherein w/v denotes weight by total volume of the composition.

6. The composition of claim 5 , further comprising from about 0.25 to about 0.35 millimolar menthol.

7. The composition of claim 6 , further comprising about 0.02% w/v benzalkonium chloride and about 0.1% w/v disodium ethylenediaminetetraacetic acid.

8. A method of treating rhytides comprising topically applying the composition of claim 1 to a person in need thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2022
From: PS THERAPY LTD.
To: PS THERAPY, INC.
Reel/Frame 060087/0448 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2019
From: HORN, GERALD
To: PS THERAPIES LTD
Reel/Frame 050210/0135 →
Continuity (2)
Provisional Application 62595656 · Dec 7, 2017
Related Publication 20190175481A1 · Jun 13, 2019